These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18380736)

  • 41. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
    Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C
    J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraarterial HCC therapy with I-131-Lipiodol.
    Risse JH; Grünwald F; Kersjes W; Strunk H; Caselmann WH; Palmedo H; Bender H; Biersack HJ
    Cancer Biother Radiopharm; 2000 Feb; 15(1):65-70. PubMed ID: 10740654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study.
    Partensky C; Sassolas G; Henry L; Paliard P; Maddern GJ
    Arch Surg; 2000 Nov; 135(11):1298-300. PubMed ID: 11074884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].
    Neeff H; Makowiec F; Harder J; Gumpp V; Klock A; Thimme R; Drognitz O; Hopt UT
    Zentralbl Chir; 2009 Apr; 134(2):127-35. PubMed ID: 19382043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis.
    Goin JE; Salem R; Carr BI; Dancey JE; Soulen MC; Geschwind JF; Goin K; Van Buskirk M; Thurston K
    J Vasc Interv Radiol; 2005 Feb; 16(2 Pt 1):195-203. PubMed ID: 15713920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil.
    Kumar A; Srivastava DN; Bal C
    J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
    J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases.
    Jang JW; Kay CS; You CR; Kim CW; Bae SH; Choi JY; Yoon SK; Han CW; Jung HS; Choi IB
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):412-8. PubMed ID: 18963538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Iodine-131-lipiodol therapy in hepatic tumours.
    Ahmadzadehfar H; Sabet A; Wilhelm K; Biersack HJ; Risse J
    Methods; 2011 Nov; 55(3):246-52. PubMed ID: 21664971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution.
    Salem R; Parikh P; Atassi B; Lewandowski RJ; Ryu RK; Sato KT; Gates VL; Ibrahim S; Mulcahy MF; Kulik L; Liu DM; Riaz A; Omary RA; Kennedy AS
    Am J Clin Oncol; 2008 Oct; 31(5):431-8. PubMed ID: 18838878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of a 188 Re-SSS lipiodol/131I-lipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma.
    Garin E; Rakotonirina H; Lejeune F; Denizot B; Roux J; Noiret N; Mesbah H; Herry JY; Bourguet P; Lejeune JJ
    Nucl Med Commun; 2006 Apr; 27(4):363-9. PubMed ID: 16531923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 131I lipiodol therapy for unresectable hepatocellular carcinoma.
    Rindani RB; Hugh TJ; Roche J; Roach PJ; Smith RC
    ANZ J Surg; 2002 Mar; 72(3):210-4. PubMed ID: 12071454
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
    Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
    Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
    Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
    Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocellular carcinoma.
    Shiraishi R; Yamasaki T; Saeki I; Okita K; Yamaguchi Y; Uchida K; Terai S; Sakaida I
    Am J Clin Oncol; 2008 Aug; 31(4):311-6. PubMed ID: 18845987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapy of hepatocellular cancer with iodine-131-Lipiodol.
    Risse JH; Menzel C; Grünwald F; Strunk H; Biersack HJ; Palmedo H
    Rom J Gastroenterol; 2004 Jun; 13(2):119-24. PubMed ID: 15229776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of hepatocellular carcinoma (HCC) with radiolabeled Lipiodol: a preliminary report.
    Park CH; Suh JH; Yoo HS; Lee JT; Kim DI; Kim BS
    Nucl Med Commun; 1987 Dec; 8(12):1075-87. PubMed ID: 2835716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemolipiodolization and prostaglandin E1 administration with use of hepatic arterial infusion port for the treatment of hepatocellular carcinoma and liver cirrhosis.
    Kakizoe S; Kakizoe K; Kakizoe Y; Kakizoe H; Kakizoe T; Kakizoe S
    Hepatogastroenterology; 1996; 43(11):1377-82. PubMed ID: 8908577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative (131)I-lipiodol therapy.
    Brans B; Lambert B; De Beule E; De Winter F; Van Belle S; Van Vlierberghe H; de Hemptinne B; Dierckx RA
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1374-9. PubMed ID: 12271421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.